Improving glaucoma management

Article

Researchers have found that giving patients a dual therapy of bimatoprost and a beta-blocker is an effective method of lowering intraocular blood pressure (IOP) in patients with open-angle glaucoma.

Researchers have found that giving patients a dual therapy of bimatoprost and a beta-blocker is an effective method of lowering intraocular blood pressure (IOP) in patients with open-angle glaucoma.

The study consisted 89 patients with an IOP of less than 21 mm Hg. During six weeks the group were given latanoprost 50 mcg plus timolol 5 mg/mL, these patients were randomized to either travoprost plus timolol or bimatoprost plus timolol for three months before switching to the opposite therapy for an additional three months.

This study has been published in the American Journal of Ophthalmology

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.